Clinical Trial Update: The Efficacy and Safety of Dapagliflozin in the Treatment of Hereditary Kidney Disease With Proteinuria in Children [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating the efficacy and safety of dapagliflozin in children with hereditary kidney diseases and proteinuria; recruitment is ongoing.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hereditary Kidney Disease

Drugs mentioned

• Dapagliflozin (dapagliflozin)

Snippet

Sponsor: Children's Hospital of Fudan University | Conditions: Pediatric Hereditary Kidney Diseases | Phase 3 | Status: RECRUITING